Atlas Trials

SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

Clinical trial NCT06936748 · RECRUITING

Trial details

NCT number
NCT06936748
Sponsor
Second Affiliated Hospital of Nanchang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2025-06-20
Primary completion
2028-06-19
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.